Clinical Trials Logo

Filter by:
NCT ID: NCT02503631 Terminated - Colorectal Cancer Clinical Trials

Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers

Start date: October 2014
Phase:
Study type: Observational

The primary objective of this study is to obtain de-identified, clinically characterized, stool and plasma specimens for use in assessing new markers for the detection of neoplasms of the digestive tract.

NCT ID: NCT02503501 Terminated - Clinical trials for Mild Cognitive Impairment

Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease

Start date: September 28, 2015
Phase: Phase 2
Study type: Interventional

This study evaluates the safety and effectiveness of intranasal (IN) glulisine in patients with amnestic mild cognitive impairment (aMCI) and probable Alzheimer's disease. Half of participants will receive IN glulisine, while the other half will receive IN placebo.

NCT ID: NCT02503410 Terminated - Clinical trials for Non-specific Chronic Low Back Pain

An Interactive Gaming-based Intervention for Back Pain

Start date: September 2015
Phase: N/A
Study type: Interventional

This study aims to compare the outcomes of a traditional, exercise-based rehabilitation intervention for chronic low back pain with the outcomes achieved by combining a traditional intervention with adjunct therapy delivered using an interactive gaming-based system for home-based therapy.

NCT ID: NCT02502799 Terminated - Clinical trials for Attention Deficit Hyperactivity Disorder

Intervention for Teens With ADHD and Substance Use

Start date: July 2015
Phase: Phase 3
Study type: Interventional

Individuals with ADHD are at markedly high risk for increased substance use and Substance Use Disorder (SUD). Given the strong evidence for the negative trajectory of individuals with co-occurring ADHD and substance use initiation, the goal of this study is to conduct a controlled examination of a brief, early intervention (BEI) for substance modified for adolescents with ADHD. Importantly, this intervention will address individuals who are at risk for problems with substance use, but do not yet meet criteria for severe SUD. Although brief interventions have been found to be effective in other populations, their efficacy in an ADHD population with emerging risk for substance use problems remains uninvestigated. This study aims to understand why some adolescents with ADHD and elevated risk for SUD respond to (BEI) and others do not. The investigators will test whether situational and individual characteristics predict substance use development and response to treatment. Further, this study will assess which types of additional treatment are most effective for youth who do not respond to the initial BEI. It is hypothesized that rates of adolescent substance use will be lower among adolescents who participate in study treatments.

NCT ID: NCT02502201 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

Environment Effect on Six-Minute Walk Test Performance

6MWTAATD
Start date: October 2015
Phase: N/A
Study type: Interventional

The purpose of this research study is to determine the effect of the environment on six-minute walk test performance in individuals with chronic obstructive pulmonary disease due to alpha-1 antitrypsin deficiency. The aim of the study is to determine the environmental impact on physical performance in this population to determine if any factors influence quality of life. This study was developed to evaluate the efficacy of the using the indoor six-minute walk test to determine eligibility for ambulatory oxygen therapy.

NCT ID: NCT02502188 Terminated - Healthy Volunteers Clinical Trials

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

Start date: July 17, 2015
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of CC-90005 in healthy subjects and subjects with moderate to severe plaque-type psoriasis.

NCT ID: NCT02502006 Terminated - Healthy Clinical Trials

Variability in Response to Non-steroidal Anti-inflammatory Drugs

Start date: November 2015
Phase: Phase 1
Study type: Interventional

This research study will evaluate inter-individual variability in the response to the non-steroidal anti-inflammatory drugs (NSAIDs), celecoxib and naproxen, among healthy adults. It will also investigate what factors, like age, sex, or genetic background, cause this variability.

NCT ID: NCT02501759 Terminated - Prostate Carcinoma Clinical Trials

Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer

Start date: May 2015
Phase: N/A
Study type: Interventional

This pilot clinical trial studies transrectal magnetic resonance imaging (MRI)-guided biopsy to see how well it works in identifying cancer in patients with suspected prostate cancer who are scheduled to undergo standard biopsy. Transrectal MRI-guided biopsy uses a thin needle inserted through the rectum into the prostate and takes a sample of tissue, guided by MRI. MRI uses magnets to take pictures of the prostate and may be able to identify cancer. Transrectal MRI-guided biopsy may be more accurate and cause patients less pain than standard ultrasound-guided biopsy. It is not yet known whether transrectal MRI-guided biopsy is more effective than ultrasound-guided biopsy in identifying prostate cancer.

NCT ID: NCT02500914 Terminated - Clinical trials for Small Cell Lung Cancer

SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

Start date: June 2015
Phase: Phase 1
Study type: Interventional

This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). SC-002 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy. The purpose of this study is to assess the safety and tolerability of SC-002 at different dose levels, to determine the highest dose of SC-002 that can be given to patients with SCLC or LCNEC, to evaluate the side effects of SC-002, and to assess the anti-cancer activity of SC-002.

NCT ID: NCT02500901 Terminated - Clinical trials for Metastatic Prostate Cancer

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Start date: March 2016
Phase: Phase 1
Study type: Interventional

This is a phase I study to determine the safety and feasibility of the combination of enzalutamide and niraparib in subjects with metastatic castration-resistant prostate cancer (CRPC).